NASDAQ:ANAB - AnaptysBio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $68.46 -2.03 (-2.88 %) (As of 12/14/2018 04:00 PM ET)Previous Close$70.49Today's Range$68.31 - $71.1052-Week Range$62.56 - $134.00Volume255,043 shsAverage Volume365,212 shsMarket Capitalization$1.91 billionP/E Ratio-45.04Dividend YieldN/ABeta3.39 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California. Receive ANAB News and Ratings via Email Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANAB Previous Symbol CUSIPN/A Webwww.anaptysbio.com Phone858-362-6295 Debt Debt-to-Equity RatioN/A Current Ratio24.10 Quick Ratio24.10 Price-To-Earnings Trailing P/E Ratio-45.04 Forward P/E Ratio-24.45 P/E GrowthN/A Sales & Book Value Annual Sales$10 million Price / Sales183.13 Cash FlowN/A Price / Cash FlowN/A Book Value$13.09 per share Price / Book5.23 Profitability EPS (Most Recent Fiscal Year)($1.52) Net Income$-30,070,000.00 Net MarginsN/A Return on Equity-14.86% Return on Assets-13.99% Miscellaneous Employees60 Outstanding Shares26,750,000Market Cap$1.91 billion OptionableOptionable AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions What is AnaptysBio's stock symbol? AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB." How were AnaptysBio's earnings last quarter? AnaptysBio Inc (NASDAQ:ANAB) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.05. The biotechnology company had revenue of $5 million for the quarter. View AnaptysBio's Earnings History. When is AnaptysBio's next earnings date? AnaptysBio is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for AnaptysBio. What price target have analysts set for ANAB? 10 equities research analysts have issued 1 year price objectives for AnaptysBio's shares. Their forecasts range from $84.00 to $162.00. On average, they anticipate AnaptysBio's stock price to reach $132.70 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price. View Analyst Price Targets for AnaptysBio. What is the consensus analysts' recommendation for AnaptysBio? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AnaptysBio. What are Wall Street analysts saying about AnaptysBio stock? Here are some recent quotes from research analysts about AnaptysBio stock: 1. According to Zacks Investment Research, "AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. " (11/9/2018) 2. Cantor Fitzgerald analysts commented, ". $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study." (10/16/2018) Has AnaptysBio been receiving favorable news coverage? News headlines about ANAB stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. AnaptysBio earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the near term. Who are some of AnaptysBio's key competitors? Some companies that are related to AnaptysBio include Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Catalent (CTLT), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO) and FibroGen (FGEN). Who are AnaptysBio's key executives? AnaptysBio's management team includes the folowing people: Mr. Hamza Suria, Pres, CEO & Director (Age 42)Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 43)Prof. Marco Londei, Chief Medical Officer (Age 61)Dr. Margaret Marino Ph.D., VP of Project Management When did AnaptysBio IPO? (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (16.37%), Janus Henderson Group PLC (13.07%), Vanguard Group Inc. (6.92%), Vanguard Group Inc (6.92%), BlackRock Inc. (6.77%) and Partner Fund Management L.P. (3.94%). Company insiders that own AnaptysBio stock include Dominic Piscitelli, Hamza Suria, Healthcare Vii LP Frazier, Holdings A/S Novo, Nicholas Lydon and Ventures Vii L P Avalon. View Institutional Ownership Trends for AnaptysBio. Which institutional investors are selling AnaptysBio stock? ANAB stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., AQR Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Asymmetry Capital Management L.P., Morgan Stanley, WINTON GROUP Ltd and Credit Suisse AG. Company insiders that have sold AnaptysBio company stock in the last year include Dominic Piscitelli, Hamza Suria and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio. Which institutional investors are buying AnaptysBio stock? ANAB stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Capital World Investors, Janus Henderson Group PLC, Vanguard Group Inc, Vanguard Group Inc., Franklin Resources Inc. and Wells Fargo & Company MN. Company insiders that have bought AnaptysBio stock in the last two years include Healthcare Vii LP Frazier and Nicholas Lydon. View Insider Buying and Selling for AnaptysBio. How do I buy shares of AnaptysBio? Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AnaptysBio's stock price today? One share of ANAB stock can currently be purchased for approximately $68.46. How big of a company is AnaptysBio? AnaptysBio has a market capitalization of $1.91 billion and generates $10 million in revenue each year. The biotechnology company earns $-30,070,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. AnaptysBio employs 60 workers across the globe. What is AnaptysBio's official website? The official website for AnaptysBio is http://www.anaptysbio.com. How can I contact AnaptysBio? AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected] MarketBeat Community Rating for AnaptysBio (NASDAQ ANAB)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 239 (Vote Outperform)Underperform Votes: 167 (Vote Underperform)Total Votes: 406MarketBeat's community ratings are surveys of what our community members think about AnaptysBio and other stocks. Vote "Outperform" if you believe ANAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANAB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low?